CDXS Share Price Performance
US$1.67
-3.94 (-70.23%)
84.8% undervalued intrinsic discount
US$11.00
Fair Value
Price US$1.67
AnalystHighTarget US$11.00
AnalystLowTarget US$2.00
AnalystConsensusTarget US$7.08
Fair ValueUS$11.00
Share Pricen/a
Codexis, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
CDXS Community Narratives
AN
Fair Value US$11 84.8% undervalued intrinsic discount
Sustainable Enzyme Engineering Will Power Expanding Biopharma Opportunities
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$2 16.5% undervalued intrinsic discount
Rising siRNA Manufacturing Risks May Delay Profitability Yet Long-Term Upside Remains
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$7.08 76.4% undervalued intrinsic discount
ECO Platform Partnerships Will Transform Pharma Manufacturing
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
Rising siRNA Manufacturing Risks May Delay Profitability Yet Long-Term Upside Remains
Catalysts About Codexis Codexis develops and scales enzymatic manufacturing technologies for siRNA and small molecule therapeutics. What are the underlying business or industry changes driving this perspective?Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$2
16.5% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
27.65% p.a.
Profit Margin
15.5%
Future PE
16.64x
Price in 2028
US$2.43
Sustainable Enzyme Engineering Will Power Expanding Biopharma Opportunities
Key Takeaways Powerful demand for sustainable biocatalysis and advancements in RNA therapeutics are driving transformative revenue and margin opportunities beyond current forecasts. Codexis' expansion, internalized supply chain, and reputation as a gold-standard partner are setting the stage for accelerated growth and industry-leading profitability.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$11
84.8% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
37.67% p.a.
Profit Margin
14.21%
Future PE
71.57x
Price in 2028
US$12.31
ECO Platform Partnerships Will Transform Pharma Manufacturing
Key Takeaways ECO platform adoption and advanced enzyme technologies drive higher-margin, recurring revenues and strengthen Codexis's competitive position in pharma and biotechnology markets. Strategic partnerships and investment in GMP capabilities expand revenue diversification, customer retention, and earnings stability while supporting long-term margin and growth improvement.Read more
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
US$7.08
76.4% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
29.27% p.a.
Profit Margin
14.21%
Future PE
55.55x
Price in 2028
US$7.91
Trending Discussion
Recently Updated Narratives
AN
Rising siRNA Manufacturing Risks May Delay Profitability Yet Long-Term Upside Remains
Fair Value: US$2 16.5% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Sustainable Enzyme Engineering Will Power Expanding Biopharma Opportunities
Fair Value: US$11 84.8% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ECO Platform Partnerships Will Transform Pharma Manufacturing
Fair Value: US$7.08 76.4% undervalued intrinsic discount
6 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Codexis, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.71
- -20.22%
- -120.82%
- 103.1%
About CDXS
- Founded
- 2002
- Employees
- 188
- CEO
- WebsiteView website
Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
